Rituximab

Rituxan, Truxima, Ruxience, Rituxan Hycela, Riabni

Biologic • Anti-CD20 monoclonal antibody

Premium

HepatotoxicNephrotoxic

Half-life

22 days (after first dose); 76 days (after fourth dose)

Protein Binding

N/A

Metabolized By

Proteolytic degradation

External

Drugs.com

Boxed warning

Fatal infusion reactions
Severe mucocutaneous reactions (SJS/TEN)
Hepatitis B reactivation
Progressive multifocal leukoencephalopathy (PML)

Clinical alerts

Boxed warning

4 boxed warnings

Nephrotoxic

Monitor renal function; avoid other nephrotoxins where possible

Hepatotoxic

Monitor liver function

Mechanism of action

Chimeric antibody targeting CD20 on B lymphocytes, causing B-cell depletion

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Granulomatosis With Polyangiitis
·Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
·Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
·Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma
·Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma

Interactions

No curated interaction pairs are recorded for Rituximab. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Infusion reactions
Infections
Tumor lysis syndrome
Cytopenias

Food, alcohol & herbal

Alcohol · minor

No significant interaction

Pharmacokinetics

Published parameters · PMID:19474567

Half-life: 22 days (after first dose); 76 days (after fourth dose)
Protein binding: N/A
Metabolised by: Proteolytic degradation
Clearance: 0.015 L/h; adult NHL and RA patients
Volume of distribution: 4 L
Renally eliminated: 0%
Model: 2-compartment

Pregnancy & lactation

Not recorded for Rituximab. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, published PK literature.

Not a substitute for clinical judgement

Rituximab

Rituxan, Truxima, Ruxience, Rituxan Hycela, Riabni

Biologic • Anti-CD20 monoclonal antibody

Premium

HepatotoxicNephrotoxic

Half-life

22 days (after first dose); 76 days (after fourth dose)

Protein Binding

N/A

Metabolized By

Proteolytic degradation

External

Drugs.com

Boxed warning

Fatal infusion reactions
Severe mucocutaneous reactions (SJS/TEN)
Hepatitis B reactivation
Progressive multifocal leukoencephalopathy (PML)

Clinical alerts

Boxed warning

4 boxed warnings

Nephrotoxic

Monitor renal function; avoid other nephrotoxins where possible

Hepatotoxic

Monitor liver function

Mechanism of action

Chimeric antibody targeting CD20 on B lymphocytes, causing B-cell depletion

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Granulomatosis With Polyangiitis
·Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
·Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
·Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma
·Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma

Interactions

No curated interaction pairs are recorded for Rituximab. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Infusion reactions
Infections
Tumor lysis syndrome
Cytopenias

Food, alcohol & herbal

Alcohol · minor

No significant interaction

Pharmacokinetics

Published parameters · PMID:19474567

Half-life: 22 days (after first dose); 76 days (after fourth dose)
Protein binding: N/A
Metabolised by: Proteolytic degradation
Clearance: 0.015 L/h; adult NHL and RA patients
Volume of distribution: 4 L
Renally eliminated: 0%
Model: 2-compartment

Pregnancy & lactation

Not recorded for Rituximab. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, published PK literature.

Not a substitute for clinical judgement

Rituximab Drug Profile | PharmaGraphX